Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Blood Advances
|
September 23, 2022
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
Jeremy S Abramson, Patrick B Johnston, Manali Kamdar, et al.
Leukemia & Lymphoma
|
February 25, 2020
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
Murielle Roussel, Benjamin Hebraud, Cyrille Hulin, et al.
The Lancet. Haematology
|
February 29, 2024
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
Michel Delforge, Krina Patel, Laurie Eliason, et al.
JTO Clinical and Research Reports
|
January 26, 2026
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial
Niels Reinmuth, Sébastien Couraud, Luis Paz-Ares, et al.
Journal of Clinical Medicine
|
January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
Esther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
Hemasphere
|
May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
European Journal of Haematology
|
April 24, 2023
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept
Maria Domenica Cappellini, Ali T Taher, Antonio Piga, et al.
Haematologica
|
March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
Michel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Leukemia & Lymphoma
|
April 10, 2020
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Katja Weisel, Meletios Dimopoulos, Philippe Moreau, et al.
Leukemia
|
August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Blood Advances
|
September 23, 2022
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
Jeremy S Abramson, Patrick B Johnston, Manali Kamdar, et al.
Leukemia & Lymphoma
|
February 25, 2020
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
Murielle Roussel, Benjamin Hebraud, Cyrille Hulin, et al.
The Lancet. Haematology
|
February 29, 2024
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
Michel Delforge, Krina Patel, Laurie Eliason, et al.
JTO Clinical and Research Reports
|
January 26, 2026
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial
Niels Reinmuth, Sébastien Couraud, Luis Paz-Ares, et al.
Journal of Clinical Medicine
|
January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
Esther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
Hemasphere
|
May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
European Journal of Haematology
|
April 24, 2023
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept
Maria Domenica Cappellini, Ali T Taher, Antonio Piga, et al.
Haematologica
|
March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
Michel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Leukemia & Lymphoma
|
April 10, 2020
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Katja Weisel, Meletios Dimopoulos, Philippe Moreau, et al.
Leukemia
|
August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
Page
of 6